Is rPFS endpoint from CAPItello-281 sufficient to adopt capivasertib + abiraterone for all PTEN-deficient mHSPC?

Not automatically for every PTEN-deficient patient. But rPFS is sufficient to establish capivasertib + abiraterone as a legitimate standard treatment option in appropriately selected patients.

CAPItello-281 was unequivocally positive for its primary endpoint: median rPFS was 33.2 versus 25.7 months, ...

We know from the STAMPEDE platform trials that PTEN loss is a poor prognostic feature. It is therefore very reasonable to identify additional options for the management of prostate cancer with PTEN loss in an effort to help our patients live longer. However, I believe more information is needed befo...

Yes, radiographic progression-free survival is a clinically important patient endpoint in prostate cancer. For my patients with metastatic prostate cancer, their first remission is typically their best remission, and keeping cancer under control is an important goal for patients. In the CAPItello-28...